Llwytho...
Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to unde...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | BMC Pulm Med |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602932/ https://ncbi.nlm.nih.gov/pubmed/28915874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0468-5 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|